FDA website shows limited availability of some doses of Lilly's Mounjaro through April
FDA website shows limited availability of some doses of Lilly's Mounjaro through April
Phương Nhung
The U.S. Food and Drug Administration's (FDA) website showed that four doses of Eli Lilly's diabetes drug, Mounjaro, would be available only in limited amounts through April 2024 due to increased demand.
According to the health regulator's website, 7.5, 10, 12.5, and 15 milligram doses of the injection will be in limited availability, while lower doses of Mounjaro were shown to be available.
Eli Lilly did not immediately respond to a Reuters' request for comment.
Soaring demand for a class of highly effective diabetes and obesity drugs known as GLP-1 agonists, which suppress appetite and promote a feeling of fullness, has led to supply constraints for drugmakers such as Lilly and Danish drugmaker Novo Nordisk .
Earlier this year, the FDA's website showed that 10, 12.5 and 15-milligram doses of the injection would have limited availability through early March.
Lilly's Mounjaro has been approved for patients with type-2 diabetes to control their blood sugar levels since 2022.
The injection, which has the active ingredient tirzepatide, gained the FDA's approval for weight loss under the brand name Zepbound in the United States last year. (Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
